Latest Antimicrobial Technology News

Iperion reported a lower loss for the year ended 31 March 2026, but its cash reserves and net assets fell sharply, leaving the NZX-listed materials company reliant on related-party funding and director support. Its Pathoglaze manufacturing operation is also being moved from Malaysia to Singapore while customer trials continue.

Powerhouse Ventures holds $6.14 million in liquid assets and advances new technology fund launch despite challenging market conditions.

Zoono Group has boosted its cash receipts by NZ$333,000 this quarter, driven by initial orders worth NZ$585,000 in its fresh food shelf-life extension sector. Despite operating losses, the company expects to sustain operations through signed contracts and inventory.

Skin Elements Limited reported a $4.01 million loss for the half-year ending December 2025, alongside a 41% revenue drop, while securing $2.5 million in fresh capital to advance its proprietary SE Formula biotechnology products.

Zoono Group has landed its first commercial orders from three new packaging partners, marking a key milestone in its fresh food shelf-life extension strategy. The company reports NZ$551,000 cash on hand as it navigates growth and funding options.

Nanoveu Limited has successfully raised $7.38 million through a strategic placement, advancing its position in advanced semiconductor and material sciences. The capital injection supports ongoing development of its innovative AI-driven SoC solutions and antimicrobial technologies.

Zoono Group has signed a five-year exclusive contract with Multisteps Pty Limited to apply its antimicrobial technology to fresh produce packaging in Australia, aiming to reduce food waste and boost sustainability.

Zoono Group has secured a five-year exclusive contract with Mpact Operations to apply its antimicrobial technology to corrugated packaging for fresh produce in South Africa and Namibia, aiming to extend shelf-life and reduce food waste.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.

Zoono Group Limited has raised an additional A$992,000 through a shortfall placement, boosting its working capital to support global expansion of its shelf-life extension technology. The company also linked CEO share incentives to ambitious sales targets, signaling confidence in growth prospects.

Nanoveu Limited has completed a $2 million capital raise through a strategic placement and exercised options, reinforcing its position in advanced semiconductor and 3D visualization technologies.